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license (http://creativemagnetic resonance imaging (MRI) contrast relate to cerebrospinal fluid (CSF) biomarkers of
Alzheimer’s disease (AD).
Methods: LCMRI contrast was quantified in 73 individuals from the DZNE Longitudinal Cognitive
Impairment and Dementia Study (DELCODE) study comprising 25 healthy elderly adults and 21 in-
dividuals with subjective cognitive decline, 16 with mild cognitive impairment, and 11 participants
with AD dementia using 3D T1-weighted fast low-angle shot (FLASH) imaging (0.75 mm isotropic
resolution). Bootstrapped Pearson’s correlations between LC contrast, CSF amyloid, and tau were
performed in 44 individuals with CSF biomarker status.
Results: A significant regional decrease in LCMRI contrast was observed in patients with AD dementia
but not mild cognitive impairment and subjective cognitive decline compared with healthy controls. A
negative association betweenLCMRI contrast and levels ofCSFamyloid but notwithCSF tauwas found.
Discussion: These results provide first evidence for a direct association between LC MRI contrast
using in vivo T1-weighted FLASH imaging and AD pathology.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease (AD); Locus coeruleus (LC); Cerebrospinal fluid (CSF); Amyloid; Tau; Magnetic resonanceimaging (MRI)1. Introduction
The locus coeruleus (LC) is the first region to develop
neurofibrillary tangles [1] and may serve a critical role in
the pathogenesis of Alzheimer’s disease (AD). It has been
previously shown that the LC can be reliably located
in vivo using neuromelanin-sensitive magnetic resonance
imaging (MRI) approaches [2–6] and that interindividualthor. Tel.:149 391 6725054; Fax:149 391 6725060.
atthew.betts@dzne.de
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e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).differences in LC MRI contrast can predict memory
performance in cognitively healthy older adults [7]. In this
study, we investigated how LC MRI contrast relates to the
pathophysiology of AD, i.e., as determined using cerebro-
spinal fluid (CSF) biomarkers. Using first data from the
DZNE Longitudinal Cognitive Impairment and Dementia
(DELCODE) study [8], we assessed how LC contrast
changes in individuals with subjective cognitive decline
(SCD), mild cognitive impairment (MCI), Alzheimer’s dis-
ease dementia (ADD), and age-matched healthy controls
(HCs) related to levels of CSF amyloid and tau. Weimer’s Association. This is an open access article under the CC BY-NC-ND
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loss of neuromelanin-containing noradrenergic neurons
would correlate with increased AD pathology.
2. Methods
2.1. Study participants
A total of 73 older adults comprising 25 HCs and 21 SCD,
16 MCI, and 11 ADD patients were recruited via the
DELCODE study of the DZNE in Germany. SCD, MCI,
and ADD were defined as previously described [8]. All pa-
tient groups (SCD,MCI, and ADD) were referrals, including
self-referrals, whereas HCs were recruited by standardized
public advertisement. For more information on subject in-
clusion criteria, refer to the study by Jessen et al. [8]. All par-
ticipants gave written informed consent before inclusion in
the study. For neuropsychological assessments and inclusion
and exclusion criteria, refer to the study by Jessen et al. [8].
All local institutional review boards and ethical committees
approved the study protocol.
2.2. CSFAD biomarker assessment
CSF AD biomarkers were determined using commer-
cially available kits according to vendor specifications:
V-PLEX Ab Peptide Panel 1 (6E10) Kit (K15200E) and
V-PLEX Human Total Tau Kit (K151LAE) (Meso Scale Di-
agnostics LLC, Rockville, MD, USA) and Innotest Phospho-
Tau(181P) (81581; Fujirebio Germany GmbH, Hannover,
Germany) as described previously [8].
2.3. MRI acquisition and determination of LC contrast
MRI data were acquired at two scanning sites, both using
a Siemens Verio scanner. Whole-brain T1-weighted fast low-
angle shot (FLASH) images were acquired using the
following parameters: 0.75 ! 0.75 ! 0.75 mm3 voxel
size, 320 ! 320 ! 192 matrix, 5.56 ms echo time, 20 msTable 1
Characteristics of participants with locus coeruleus imaging and cerebrospinal flu
HCs SCD
N 25 21
Age (years) 68.0 (4.7) 70.0
Sex (M:F) 9:16 13:8
Education (years) 15.2 (2.6) 15.7
MMSE 29.4 (0.9) 29.0
ADAS delayed recall 8.3 (1.9) 7.2
N 17 10
CSF TTau (pg/mL) 329.9 (139.9) 269
CSF PTau181 (pg/mL) 46.0 (17.5) 36.5
CSF Ab42/Ab40 0.1 (0.02) 0.1
CSF Ab42/PTau181 20.0 (4.2) 20.2
CSF Ab42/TTau 2.9 (0.9) 2.8
Hulstaert ratio 1.4 (0.4) 1.3
Abbreviations: M, male; F, female; HC, healthy controls; SCD, subjective cognit
dementia; CSF, cerebrospinal fluid.
*P , .001 indicates significant differences compared with HCs (one-way ANO
yP , .01 indicates significant differences compared with HCs (one-way ANOV
zP , .05 indicates significant differences compared with HCs (one-way ANOVrepetition time, 23 flip angle, 130 Hz/pixel bandwidth, 7/
8 partial Fourier, and 13:50 min scan duration as previously
reported [5]. For a full description of the MRI protocol, refer
to the study by Jessen et al. [8]. Images were sinc interpo-
lated to 0.375 mm3 resolution before manual segmentation
of the LC. Median LC signal and contrast ratios were deter-
mined relative to reference regions delineated in the rostral
pontomesencephalic area as described previously [5]. LC
signal contrast changes were also assessed in the rostral,
middle, and caudal portions of the LC by splitting each indi-
vidual’s LC mask into three equally sized segments using
FSL Maths in FSL, version 5.0 (http://fsl.fmrib.ox.ac.uk).
3. Results
3.1. Demographic, cognitive, and clinical data
The results presented are from 73 individuals classified as
HCs (n5 25; 9 males; 68 years) and SCD (n5 21; 13 males;
70 years), MCI (n5 16; 12 males; 71 years), or ADD patients
(n5 11; 3 males; 71 years). In these individuals, Alzheimer’s
Disease Assessment Scale (ADAS) delayed recall scores were
lower in patients with MCI and ADD (F3,69 5 39.3, both
P , .001) and Mini-Mental Status Examination (MMSE)
scores were lower in patients with ADD (F3,69 5 60.0,
P , .0001) but not in MCI or SCD compared with HCs
(one-way Analaysis of Variance (ANOVA) with Bonferroni
post hoc tests). A significant difference in sex (F3,69 5 4.3,
P 5 .01) but not in age and education was observed between
groups. In 44 of these individuals with CSF biomarker status,
CSF total tau (TTau) and phospho tau (PTau) values were
significantly higher in patients with ADD than HCs
(F3,405 10.0, P, .0001; F3,405 7.7, P, .001, respectively),
whereas CSF Ab42 levels were significantly decreased in pa-
tients with MCI and ADD (F3,40 5 11.4, both P  .01)
compared with HCs. In patients with MCI and ADD, a signif-
icant decrease in Ab42/PTau181 (F3,405 12.6, both P  .02),
Ab42/TTau (F3,40 5 12.7, both P  .003), and the Hulstaertid biomarker status
MCI ADD
16 11
(5.9) 71.3 (5.5) 71.4 (6.5)
12:4 3:8
(2.8) 14.4 (2.9) 12.8 (2.6)
(1.1) 28.2 (1.2) 22.7 (2.8)*
(2.0) 4.2 (2.3)* 1.4 (1.6)*
10 7
.0 (95.0) 598.7 (314.9) 883.7 (502.2)*
(12.2) 64.0 (27.3) 106.6 (69.2)y
(0.01) 0.07 (0.03)z 0.05 (0.02)*
(3.8) 12.5 (9.1)z 5.8 (6.0)*
(1.0) 1.5 (1.2)y 0.6 (0.6)*
(0.4) 0.8 (0.5)y 0.4 (0.3)*
ive complaints; MCI, mild cognitive impairment; ADD, Alzheimer’s disease
VAwith Bonferroni post hoc tests).
A with Bonferroni post hoc tests).
A with Bonferroni post hoc tests).
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HCs (all values reported in Table 1).
3.2. Locus coeruleus contrast measures
MRI data from 73 individuals are presented of which 42
individuals (16 HCs and 12 SCD, 8 MCI, and 6 ADD pa-
tients) were from MRI scanning site 1 and 31 individuals
(9 HCs and 9 SCD, 8 MCI, and 5 ADD patients) were
from scanning site 2. No significant difference in bilateral
LC contrast in HCs and patients with SCD and MCI was
observed across sites (all P  .2; Wilcoxon rank-sum test).
However, a significant difference in LC MRI contrast in in-
dividuals with ADD across sites was found (Z 5 22.1;
P5 .034). In all individuals, significantly higher LC contrast
was observed in left compared with right LC hemispheres
(Z527.0, P, .0001; Wilcoxon signed-ranks test), consis-
tent with previous findings [5]. A significant difference be-
tween bilateral LC contrast and diagnosis was observed
(c2 5 9.8, P 5 .02; Kruskal-Wallis test), whereby LC
contrast was significantly lower in patients with ADD than
HCs (Z 5 22.2, P 5 .02; post hoc Wilcoxon rank-sum
test) as shown in Fig. 1A. Assessment of LC contrast in
each rostrocaudal third revealed a significant decline in
rostral (Z 5 22.3, P 5 .02) and middle (Z 5 22.2,
P 5 .02) but not caudal (Z 5 21.3; P 5 .2) LC contrast in
patients with ADD compared with HCs (Fig. 1B). No signif-
icant difference in signal intensity in the reference region
(P 5 .3) was observed across groups.
3.3. Relationship between LC contrast and CSF
biomarkers
We established the relationship between LC contrast and
CSF biomarkers in 44 participants using bootstrapped Pear-
son’s partial correlations set at 1000 iterations using site,
age, sex, and diagnosis as covariates. To minimize the num-
ber of tests, bilateral LC contrast values were used for all
correlational analyses.
A significant negative correlation between LC contrast
and Ab42/Ab40 (r 5 20.58, 95% CI [20.74, 20.36],
P , .001), the Hulstaert ratio (r 5 20.56, 95% CI [20.74,
20.29], P , .001), Ab42/PTau181 (r 5 20.46, 95% CI
[20.68, 20.15], P 5 .004), and Ab42/TTau (r 5 20.44,
95% CI [20.69, 20.13] P 5 .005) was observed
(Fig. 1C). However, no significant relationship between
LC contrast and PTau (r 5 0.24, 95% CI [20.11, 0.54],
P 5 .13) or TTau (r 5 0.28, 95% CI [20.07, 0.57],
P 5 .08) was found. All correlations were corrected for
multiple comparisons (Bonferroni-corrected P , .05).
To assess the relationship between LC contrast and CSF
biomarker status within each LC third, bootstrapped Pear-
son’s partial correlations revealed a significant negative cor-
relation between LC contrast and Ab42/Ab40 (r 5 20.57,
95% CI [20.74, 20.35], P , .0001), the Hulstaert ratio
(r 5 20.57, 95% CI [20.75, 20.34], P , .0001), Ab42/
PTau181 (r 5 20.45, 95% CI [20.65, 20.20], P 5 .004),and Ab42/TTau (r 5 20.44, 95% CI [20.69, 20.17],
P 5 .004) within the rostral third of the LC. A significant
negative correlation between LC contrast and Ab42/Ab40
(r 5 20.52, 95% CI [20.70, 20.29], P 5 .001), the
Hulstaert ratio (r 5 20.48, 95% CI [20.69, 20.20],
P 5 .002), and Ab42/PTau181 (r 5 20.42, 95% CI
[20.64, 20.12], P 5 .007) was also observed within the
middle LC third, but no significant associations were found
in the caudal LC third after Bonferroni correction for multi-
ple comparisons (all r , 20.32, P . .01). Furthermore, no
significant relationship between LC contrast and PTau181
and TTau in any LC third was observed after Bonferroni
correction for multiple comparisons.4. Discussion
Consistent with our hypothesis, a significant decrease in
LC MRI contrast was observed in patients with ADD
compared with healthy older adults, which was regionally
confined to the rostral/middle third of the LC. We also iden-
tified a direct association between LC contrast and CSF
biomarkers of AD, in particular with Ab42/Ab40, Ab42/
PTau181, and the Hulstaert ratio; however, no significant as-
sociation between LC contrast and CSF tau (both PTau and
TTau) was observed.
In theCSF, increasing levels of TTau and decreasing levels
of Ab42 provide indirect measures of extracellular amyloid
aggregates and intracellular accumulation of hyperphos-
phorylated tau, respectively [10]. In the sample presented,
significantly higher CSF tau and decreased CSF Ab42/Ab40
levels were observed in patients with MCI and ADD
compared with HCs consistent with more advanced AD pa-
thology. However, differences in LC MRI contrast only
significantly correlatedwithCSFAb42/Ab40 and not CSF tau.
The significant decline in LC MRI contrast in ADD is
consistent with previous reports using LC imaging in AD
[11,12]. In addition, the regional AD-related decline in LC
MRI contrast observed by Dordevic et al., 2018, is consistent
with the reduction in LC MRI contrast in the rostral/middle
thirds of the LC in ADD found in this study. It is interesting
that the significant decline in LC contrast in the rostral/mid-
dle portions of the LC also shows greatest cell loss in AD
[13]. In this regard, a positive association with LC contrast
and CSF amyloid would have been expected. However, a
significant negative association was found whereby LC
contrast was higher in individuals with lower CSF Ab42,
which appeared to be predominantly driven by HCs and
MCI patients. Thus, one explanation may be that higher
LC contrast indicates greater resilience to remain in a HC/
MCI stage (as opposed to an ADD stage) at a given level
of CSF Ab. Indeed, protective effects of the LC-
noradrenergic system have been described previously
[14–16]; however, this hypothesis remains speculative at
this time. In this sample, no significant association
between LC contrast and CSF tau was observed, which
may be due to the limited sample size presented. Thus,
Fig. 1. (A) LCMRI contrast in 73 participants comprising HCs and individuals with SCD,MCI, and ADD. *P, .05 indicates significant differences in LCMRI
contrast compared with HCs (Kruskal-Wallis test with post hoc Wilcoxon rank-sum test). In (B), LC contrast plotted across each LC third in HCs and ADD
patients only. * P, .05 indicates significant differences compared with HC (Wilcoxon rank-sum tests). (C) Bootstrapped Pearson’s partial correlations between
LC contrast and CSF levels of Ab42/Ab40, the Hulstaert ratio, and Ab42/PTau in 44 individuals with CSF biomarker status. Plots displayed are partial residuals
controlling for site, age, sex, and diagnosis. Color codes indicate HCs (blue), SCD (green), MCI (orange), and ADD (purple). Asterisks highlight significant
correlations (***P, .001; **P, .01). Abbreviations: LC, locus coeruleus; MRI, magnetic resonance imaging; HC, healthy controls; SCD, subjective cognitive
decline; MCI, mild cognitive impairment; ADD, Alzheimer’s disease dementia; CSF, cerebrospinal fluid.
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ascertain how AD pathology may influence LC contrast.
In conclusion, these preliminary findings demonstrate a
regional decline in LC MRI contrast in ADD and provide
first evidence for a direct association between changes in
LCMRI contrast and CSF biomarkers of AD. The significant
negative relationship between LC contrast and CSF Ab42/
Ab40 suggests differences in LC neuromelanin identified us-
ing T1-weighted FLASH imaging may be useful to investi-
gate LC-related vulnerability and resilience in the face of
Alzheimer’s pathology.
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(SPC WP 3.3.1).RESEARCH IN CONTEXT
1. Systematic review: A literature search on PubMed
revealed three studies investigating locus coeruleus
(LC) magnetic resonance imaging (MRI) contrast
changes in Alzheimer’s disease (AD). However, no
study to date had investigated the relationship be-
tween LC MRI contrast and cerebrospinal fluid
(CSF) biomarkers of AD.
2. Interpretation: We observed reduced MRI contrast in
the rostral/middle third but not caudal third of the LC
in AD dementia compared with healthy controls
consistent with AD neuropathology. Changes in LC
MRI contrast negatively correlated with levels of
CSF amyloid.
3. Future direction: Additional analyses using larger
sample sizes are required to ascertain how the clin-
ical progression of AD pathology may influence
LC MRI contrast.References
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